HSA warns of atezolizumab-related SCARs, SJS and TEN
- PDF / 150,760 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 83 Downloads / 234 Views
1
HSA warns of atezolizumab-related SCARs, SJS and TEN The Singaporean Health Sciences Authority (HSA) has advised that a Dear Healthcare Professional Letter from Hoffman-La Roche warns of the risk of severe cutaneous adverse reactions (SCARs) including Stevens Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients receiving atezolizumab [Tecentriq]. The Singaporean Tecentriq package insert will be updated with safety information on this risk. Healthcare professionals are advised to refer patients with suspected SCARs to a dermatologist for further diagnosis and management. Atezolizumab should be withheld in patients with suspected SJS or TEN, and permanently withdrawn in patients with confirmed SJS or TEN of any grade. Caution is advised when use of atezolizumab is being considered in a patient who experienced a previous severe or life-threatening cutaneous adverse reaction during treatment with another immune-stimulatory cancer drug. HSA - Health Sciences Authority. Tecentriq (atezolizumab): A new identified risk of severe cutaneous adverse reactions. Internet Document : 11 Nov 2020. Available from: URL: https://www.hsa.gov.sg/announcements/dear-healthcare-professional-letter/tecentriq-(atezolizumab)-a-new-identified-risk-of-severe-cutaneous-adverse803518260 reactions
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 28 Nov 2020 No. 1832
Data Loading...
